CAJ | 학술논문

目的：观察瑞舒伐他汀对老年2型糖尿病脂代谢紊乱患者的降脂疗效以及对血同型半胱氨酸（Hcy）、超敏C反应蛋白（hs-CRP）的影响，探讨其对血管内皮的保护作用。方法60例老年2型糖尿病合并脂代谢紊乱的患者随机分为对照组和治疗组，每组各30例。对照组给予常规降糖治疗，治疗组在常规降糖治疗基础上给予瑞舒伐他汀10 mg·d－1，睡前一次口服，观察3个月，比较两组治疗前后总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、Hcy和hs-CRP的变化。结果两组治疗前血脂、Hcy、hs-CRP水平无显著性差异（P #0．05）。治疗后两组的TC、TG、LDL-C、Hcy 、hs-CRP水平均下降，HDL-C水平均升高，其中治疗组患者血脂、Hcy 、hs-CRP的变化水平较对照组明显，差异有统计学意义（P＜0．05）。结论瑞舒伐他汀对老年糖尿病合并脂代谢紊乱的患者降脂作用疗效确切、使用方便安全，且能有效降低血清Hcy、hs-CRP水平。
목적：관찰서서벌타정대노년2형당뇨병지대사문란환자적강지료효이급대혈동형반광안산（Hcy）、초민C반응단백（hs-CRP）적영향，탐토기대혈관내피적보호작용。방법60례노년2형당뇨병합병지대사문란적환자수궤분위대조조화치료조，매조각30례。대조조급여상규강당치료，치료조재상규강당치료기출상급여서서벌타정10 mg·d－1，수전일차구복，관찰3개월，비교량조치료전후총담고순（TC）、감유삼지（TG）、고밀도지단백담고순（HDL-C）、저밀도지단백담고순（LDL-C）、Hcy화hs-CRP적변화。결과량조치료전혈지、Hcy、hs-CRP수평무현저성차이（P #0．05）。치료후량조적TC、TG、LDL-C、Hcy 、hs-CRP수평균하강，HDL-C수평균승고，기중치료조환자혈지、Hcy 、hs-CRP적변화수평교대조조명현，차이유통계학의의（P＜0．05）。결론서서벌타정대노년당뇨병합병지대사문란적환자강지작용료효학절、사용방편안전，차능유효강저혈청Hcy、hs-CRP수평。
Objective To observe the effects of rosuvastatin on blood lipids,Hcy,hs-CRP in type 2 diabetes mellitus patients complicat-ed by lipid metabolism disorder.Discuss the protection of vascular endothelial function.Methods Sixty cases of elderly diabetes melli-tus patients with disorder of lipid metabolism were randomly divided into the treatment group and the control group,with 30 cases in each group.Routine hypoglycemic therapies were given to both groups,and rosuvastain 10 mg po qn were given in the treatment group. Each case was observed for 3 months,comparing the results of two groups in terms of TC,TG,HDL-C,LDL-C,Hcy and hs-CRP.Results The blood lipids levels,the Hcy and the hs-CRP of two groups before treatment had no significant difference(P # 0.05).The levels of TC,TG,HDL-C,LDL-C,Hcy and hs-CRP in two groups were all decreased compare with those before treatment,Whereas the HDL-C was increased.Improvements in the treatment group on the blood lipids,Hcy and hs-CRP are more significant than the control group (P<0.05).Conclusions Rosuvastatin is not only to play the role of blood lipids regulation,but also to be more effective in reducing serum Hcy and hs-CRP in type 2 diabetes mellitus complicated by lipid metabolism disorder.